Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) has issued an update.
On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion covering the shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright & Co., LLC, originally established under a September 5, 2025 sales agreement. The opinion confirms the validity of shares that may be sold and clarifies certain legal matters tied to the offering, without altering the existing terms of the program, thus providing additional assurance to participants in the company’s ongoing capital-raising effort.
The most recent analyst rating on (SXTP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Neutral.
The score is held down primarily by very weak fundamentals (outsized losses and ongoing cash burn) and a significant Nasdaq delisting risk. Technical signals are comparatively supportive, but valuation is constrained by continued unprofitability and no dividend support.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. operates in the pharmaceutical industry and is listed as a public company. It focuses on issuing and selling shares of its common stock through an at-the-market equity offering program, using HC Wainwright & Co., LLC as its sales agent to access capital markets on an ongoing basis.
Average Trading Volume: 4,548,051
Technical Sentiment Signal: Sell
Current Market Cap: $6.25M
Learn more about SXTP stock on TipRanks’ Stock Analysis page.